Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session

1103 - Prognostic implication of Inflammation-based Prognostic Scores in Patients with Intrahepatic Cholangiocarcinoma (iCCA) Treated with First-line Gemcitabine Plus Cisplatin (GEMCIS)


09 Sep 2017


Poster display session


Cytotoxic Therapy;  Hepatobiliary Cancers


Hyungwoo Cho


Annals of Oncology (2017) 28 (suppl_5): v209-v268. 10.1093/annonc/mdx369


H. Cho, C. Yoo, K. Kim, H. Chang, B. Ryoo

Author affiliations

  • Department Of Oncology, Asan Medical Center, University of Ulsan College of Medicine, 138-736 - Seoul/KR


Abstract 1103


There is increasing evidence that inflammation-based prognostic scores have prognostic value in several cancer types, including iCCA. However, most of the studies are focused on evaluating their value in patients with resectable disease. We retrospectively evaluated the prognostic implication of inflammation-based prognostic scores including modified Glasgow Prognostic Score (mGPS) based on serum albumin and C-reactive protein, neutrophil-lymphocyte ratio (NLR), and platelet-lymphocyte ratio (PLR) in patients with unresectable or metastatic iCCA.


Between April 2010 and May 2015, a total of 296 patients with histologically documented advanced iCCA were treated with first-line GEMCIS in Asan Medical Center, Seoul, Korea. Of these, 257 patients had complete data for inflammation-based prognostic scores and were included in this study. Primary endpoint was overall survival (OS).


Median age was 59 years (range, 27-78) and 158 patients (61.5%) were male. Initially metastatic disease was the most common disease status at GEMCIS (n = 170, 66.1%) followed by recurrence after surgery (n = 44, 17.1%) and locally advanced unresectable disease (n = 43, 16.7%). With a median follow up duration of 25.0 months (95% CI, 19.6-30.4), median OS was 9.1 months (95% CI, 8.0-10.2). In univariate analyses, high mGPS and NLR scores were associated with poorer OS (mGPS 1-2 vs 0: median 6.9 vs 14.1 months, p 


The current study suggests that mGPS might be the relevant prognostic index which can stratify the survival outcomes of patients with unresectable or metastatic iCCA who received first-line GEMCIS.

Clinical trial identification

Legal entity responsible for the study

Asan Medical Center, University of Ulsan College of Medicine.




All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.